breast cancer

[Cell Death & Disease] Integrated affinity purification combined with mass spectrometry and TCGA analysis identified a cell cycle-related E3 ubiquitin ligase, checkpoint with forkhead and ring finger domains (CHFR), as a key negative regulator of zinc finger E-box-binding homeobox 1 (ZEB1) in TNBC.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers developed dual-mechanism estrogen receptor (ER) inhibitors that caused alternate, noncanonical structural perturbations of the receptor ligand-binding domain to antagonize proliferation in ER-positive breast cancer cells and in allele-specific resistance models.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators manipulated tripartite motif–containing 47 (TRIM47) expression in estrogen receptor–positive breast cancer cells MCF-7 and its 4-hydroxytamoxifen (OHT)-resistant derivative OHTR, which was established in a long-term culture with OHT. TRIM47 promoted both MCF-7 and OHTR cell proliferation.

[HUTCHMED] HUTCHMED initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer or advanced endometrial cancer in the US. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor inhibitor, fruquintinib, to anti-programmed death-1 antibody tislelizumab in inducing activity to immune checkpoint inhibitors.

[Merck & Co. Inc.] Merck, Inc. announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA). KEYTRUDA is approved for the treatment of patients with PD-L1-positive, hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative, inoperable or recurrent breast cancer, based on the results of the Phase 3 KEYNOTE-355 trial.

[Cell Death Discovery] The functional roles of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ)–DAAM1 axis and their regulator microRNA-613 in breast cancer cells and associated molecular mechanisms were demonstrated in vitro.